ArticleViruses2022
SARS-CoV-2 Seroprevalence among Canadian Blood Donors: The Advance of Omicron.
Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- The impact of statistical adjustment for assay performance on inferences from SARS-CoV-2 serological surveillance studies.American journal of epidemiology · 2025Article
- Article
- Canada's approach to SARS-CoV-2 sero-surveillance: Lessons learned for routine surveillance and future pandemics.Canadian journal of public health = Revue canadienne de sante publique · 2024Article
- SARS-CoV-2 vaccination in Canadian blood donors: Insight into donor representativeness of the general population.Vaccine: X · 2024Article
- Temporal trends in disparities in COVID-19 seropositivity among Canadian blood donors.International journal of epidemiology · 2024Article
- SARS-CoV-2 seroprevalence in Nova Scotia blood donors.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.Microbiology spectrum · 2023Article
- The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Seroprevalence of Anti-SARS-CoV-2 Antibodies Following the Omicron BA.1 Wave.International journal of environmental research and public health · 2023Article
- An expanded role for blood donor emerging pathogens surveillance.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence of the SARS-CoV-2 Omicron variant in late 2021, Canadian public health case/contact testing was scaled back due to high infection rates with milder symptoms in a highly vaccinated population. We monitored the seroprevalence of SARS-CoV-2 nucleocapsid (anti-N) and spike protein (anti-S) antibodies in blood donors across Canada from September 2021 to June 2022 in 202,123 randomly selected samples. Multivariable logistic regression of anti-N positivity with month, age, sex, racialization, region, material and social deprivation (based on postal code) identified as independent predictors. Piece-wise logistic regression analysed the association between anti-S concentration and month, and anti-N/anti-S positivity. Infection-related seroprevalence (anti-N positive) was 4.38% (95% CI: 3.96, 4.81) in September reaching 50.70% (50.15, 52.16) in June; nearly 100% were anti-S positive throughout. Anti-N positivity was associated with younger age, male sex, the Alberta and Prairies regions, greater material deprivation and less social deprivation (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.